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Onset of depressive symptoms after the age of 65, or late-life depression (LLD), is common
and poses a signiﬁcant burden on affected individuals, caretakers, and society. Evidence
suggests a unique biological basis for LLD, but current hypotheses do not account for its
pathophysiological complexity. Here we propose a novel etiological framework for LLD,
the age-by-disease biological interaction hypothesis, based on the observations that the
subset of genes that undergoes lifelong progressive changes in expression is restricted
to a speciﬁc set of biological processes, and that a disproportionate number of these
age-dependent genes have been previously and similarly implicated in neurodegenera-
tive and neuropsychiatric disorders, including depression. The age-by-disease biological
interaction hypothesis posits that age-dependent biological processes (i) are “pushed”
in LLD-promoting directions by changes in gene expression naturally occurring during
brain aging, which (ii) directly contribute to pathophysiological mechanisms of LLD, and
(iii) that individual variability in rates of age-dependent changes determines risk or resiliency
to develop age-related disorders, including LLD. We review observations supporting this
hypothesis, including consistent and speciﬁc age-dependent changes in brain gene expres-
sion and their overlap with neuropsychiatric and neurodegenerative disease pathways.
We then review preliminary reports supporting the genetic component of this hypothe-
sis. Other potential biological mediators of age-dependent gene changes are proposed.
We speculate that studies examining the relative contribution of these mechanisms to
age-dependent changes and related disease mechanisms will not only provide critical infor-
mation on the biology of normal aging of the human brain, but will inform our understanding
of age-dependent diseases, in time fostering the development of new interventions for
prevention and treatment of age-dependent diseases, including LLD.
Keywords: late-life depression, depression,molecular aging, gene expression, telomere, oxidative stress, epigenetic
modifications
INTRODUCTION
Among elderly individuals, depressive symptoms are common and
burdensome. Approximately 1% of individuals over the age of 65
meet criteria for major depressive disorder (MDD), as deﬁned by
the diagnostic and statistical manual of mental disorders, fourth
edition, text revision (DSMIV-TR; American Psychiatric Asso-
ciation, 2000), a prevalence lower than that in younger adults
(Kessler et al., 2003). Another 15–25%, however, experience
depressive symptoms that, while not meeting criteria for MDD,
do cause signiﬁcant distress and interfere with daily functioning
(Koenig and Blazer, 1992). In this article, the term late-life depres-
sion (LLD) will be used to refer to individuals over the age of 65
who for the ﬁrst time in their lives meet criteria for MDD or dis-
play clinically signiﬁcant depressive symptoms. Individuals with
LLD experience greater functional disability (Dombrovski et al.,
2007) and cognitive decline (Lenze et al., 2005) than those with-
out. Further, they are at increased risk of morbidity and mortality
from medical illness (Ganguli et al., 2002). LLD also appears to
contribute to increased rates of suicide among older individuals
(Van Orden and Conwell, 2011).
The biological substrates of LLD are being characterized and
several hypotheses for the etiology and pathophysiology of LLD
have been proposed, including the vascular hypothesis (Alex-
opoulos et al., 1997), inﬂammation hypothesis (Alexopoulos and
Morimoto, 2011), and dementia prodrome hypothesis (Byers and
Yaffe, 2011; reviewed in McKinney and Sibille, 2012). Here, we
propose an alternative and complementary hypothesis, which we
termed the age-by-disease biological interaction hypothesis of
LLD. Central to this hypothesis is the concept of molecular aging
of the human brain. An earlier version of this hypothesis has been
described elsewhere (McKinney and Sibille, 2012).
MOLECULAR AGING OF THE HUMAN BRAIN
Despite its critical importance to a population that is growing
older, “normal” brain aging is understudied. This may be due to
the often expressed, but false belief held by many that aging is
inescapable, broad-ranging and non-speciﬁc. Studies that have
investigated biological aging have revealed speciﬁc changes and
thus avenues for intervention. At the cellular level in the human
brain, morphological and stereological studies reveal a decrease
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in neuron volumes, a small loss or no change in cell numbers
(Morrison and Hof, 1997; Pakkenberg and Gundersen, 1997), and
a progressive thinning of cortical thickness, affecting both gray
and white matter (Resnick et al., 2003; Sowell et al., 2003). Sim-
ilar structural changes with age have been demonstrated in the
brains of animal models (Jucker and Ingram, 1997; Peters, 2002).
At the molecular level in animal models, less than 10% of brain-
expressed genes exhibit age-related changes in gene expression
(Lee et al., 1999, 2000; Jiang et al., 2001; Blalock et al., 2003; Sibille
et al., 2007). Similar numbers have been reported in studies of
human tissue (Lu et al., 2004; Avramopoulos et al., 2011). In one
such study of human tissue from the prefrontal cortices of sub-
jects aged 13–79, our group used gene microarray technology to
investigate age-related changes in gene expression and reported
that approximately 7.5% of genes changed signiﬁcantly with aging
(Erraji-Benchekroun et al., 2005). Other studies have conﬁrmed
these results, identifying a maximum of ∼10% of all detected
genes, depending on sample size and analytical power of the
respective studies (Yankner et al., 2008; Glorioso et al., 2011). Of
note, not only is the identity of the genes and gene classes that
are affected with aging consistent among studies, but so are the
directions of change.
Interestingly, the identity of the geneswhose expression changes
with age suggests that speciﬁc cellular populations and biolog-
ical processes are selectively affected by the aging process. For
instance, expression of genes playing a role in glial-mediated
inﬂammation, oxidative stress responses, mitochondrial func-
tion, synaptic function and plasticity, and calcium regulation
and neuropeptide signaling have consistently been shown across
multiple studies to be affected by aging, while numerous other
neuronal and glial genes remain apparently unchanged (Yankner
et al., 2008; Glorioso and Sibille, 2011). Overall, age-upregulated
genes are mostly of glial origin and related to inﬂammation
and cellular defenses, while downregulated genes display mostly
neuron-enriched transcripts relating to cellular communication
and signaling (Erraji-Benchekroun et al., 2005).
Using the expression levels of the age-dependent genes and
their expected trajectories with age, we have generated predicted
ages of individual subjects from which the brain tissue was sam-
pled, and demonstrated that this predicted age is highly correlated
with the chronological age of that individual (Erraji-Benchekroun
et al., 2005; Glorioso and Sibille, 2011; Glorioso et al., 2011). We
have termed this predicted age the “molecular age”. These ﬁnd-
ings suggest that gene expression changes with age can be used as
biomarkers for brain aging.
MOLECULAR AGING AND BRAIN-RELATED DISEASE
PATHWAYS
This correlation between molecular and chronological ages is
robust in individuals without neurodegenerative and neuropsy-
chiatric disorders (Erraji-Benchekroun et al., 2005), but inves-
tigations of individual genes suggest that the molecular age or
individual gene trajectory can deviate from chronological age in
individuals with these disorders. To illustrate this phenomenon,
one can look at somatostatin (SST), a signaling neuropeptide
that is expressed in a subpopulation of gamma-aminobutyric acid
(GABA)-positive inhibitory interneurons (Viollet et al., 2008). We
have demonstrated that expression of SST decreases progressively
with age in individuals without neurodegenerative and neuropsy-
chiatric disorders such that expression levels at 70 years of age
are approximately 40–50% of those at 20 years of age (Erraji-
Benchekroun et al., 2005; Tripp et al., 2011; Figure 1A). SST is
also downregulated in individuals with MDD. Interestingly, the
magnitude and direction of change in SST expression with age is
similar to that of control individuals, but the absolute values of
SST expression are lower at most ages in individuals with MDD
compared to those without (Sibille et al., 2011; Tripp et al., 2011;
Figure 1A, top panel). Similar ﬁndings have been observed in sub-
jects with schizophrenia (Morris et al., 2008; Figure 1A, bottom
panel).
The relationship between gene expression of a disorder-
associated gene and aging is not limited to SST. In fact, genome-
wide investigations have reported that up to a third of age-
regulated genes in the human brain have been at some point
associated in the literature with neurodegenerative (Alzheimer’s,
Parkinson’s, and Huntington’s diseases, amyotrophic lateral scle-
rosis) and neuropsychiatric disorders (bipolar depression, major
depression, and schizophrenia; see Figure 3 in Glorioso et al., 2011
for details). Not only do the genes relevant to these brain disor-
ders show age-related changes, but the direction of the changes
that occur with age is almost always in the direction thought to
cause or promote diseases. See Table 1 in Glorioso et al. (2011) for
a list of approximately 40 top candidate disease genes that exhibit
agreement between age- and disease-related changes. Studies of
gene expression in Alzheimer’s disease (AD) and normal aging
ﬁnd that most of the changes in gene expression that occur in
normal aging also occur in AD, only in greater magnitude (Miller
et al., 2008; Avramopoulos et al., 2011). The difference in the mag-
nitude of change in gene expression between individuals with
brain disease and those without during aging is attributable to
the disease. Our hypothesis posits that it is these changes that
drive the disease process; however, it cannot be ruled out that
these additional changes in magnitude are the result of the dis-
ease process rather than the cause. That said, there are certainly
genes for which it is known that the age-related direction of
change in gene expression directly causes, rather than is a conse-
quence of, the disease, for example, the Parkinson’s disease genes
PINK1 and DJ1/PARK7. The expression of these genes progres-
sively declines with age and it is known that individuals with loss of
expression/function mutations in these genes develop Parkinson’s
disease (Schapira, 2008). In contrast, relatively fewer of the larger
pool of genes that do not display age-dependent changes (<5%),
are associated with neurodegenerative and neuropsychiatric
diseases.
Recently, we have further investigated the relationship between
age, gene changes, and neuropsychiatric disorders, speciﬁcally in
the context of MDD (Douillard-Guilloux et al., 2012). Results
demonstrated that most MDD-related genes were frequently age-
regulated in both MDD and in control subjects, and that the
effects of MDD and age were positively correlated. Moreover,
most genes that are age-dependent in control subjects displayed
greater age effects in MDD subjects, and the overall increased
prevalence of age effects on genes in MDD subjects corresponded
to similar trends in controls, rather than representing de novo age
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FIGURE 1 | (A) Somatostatin expression decreases with age in control
subjects. Individuals with MDD (top panel) and schizophrenia (bottom panel)
display lower levels of expression than control subjects at most ages,
together prompting the hypothesis that decreased expression of
somatostatin in depression and schizophrenia may represent early brain
age-related molecular phenotypes in these individuals, which would render
these subjects more vulnerable to developing psychiatric diseases. (B) Based
on similar age and disease observations for numerous additional genes, we
have proposed a model of “age-by-disease biological interaction” (Glorioso
et al., 2011). In this model, change in expression of disease-related genes (a
decrease is shown) across a threshold (horizontal blue line) marks the onset
of disease symptoms. Changes in the trajectory of age-related changes in
expression of disease-related genes (Y-axis) determine at what age (X-axis),
or even if, an individual develops disease symptoms (vertical red arrows).
Modulators (black arrows) may thus place an individual on “at risk” or
“protected” trajectory. Per this model, individuals with LLD may have
modulators, genetic or environmental, that place them on an “at risk”
trajectory for developing mood symptoms. Figures are adapted from Morris
et al. (2008), Tripp et al. (2011), Glorioso and Sibille (2011), and McKinney and
Sibille (2012).
effects. This systematic correlation between age-dependent and
depression-related changes, with greater effects in depressed sub-
jects, further suggests that normal brain aging is a risk factor for
biological changes observed in MDD subjects.
One interpretation of these observations is that age-dependent
changes (i.e., molecular aging) are on an earlier trajectory in indi-
viduals who developMDD and potentially other neuropsychiatric
disorders. However, it is important to note that these studies are
cross-sectional and do not follow the longitudinal progression
of gene changes within individuals, so it is not known whether
age-dependent changes are on an earlier trajectory, or whether
changes occurred at earlier time points and were ﬁxed at lower
levels, for instance in the case of SST. So while we hypothesize
that age may be pushing the expression of genes in disorder-
causing directions, an alternate scenario is that of earlier and
ﬁxed changes, which then act as latent vulnerability factors that
are revealed with advancing age, resulting in increased vulner-
ability to develop neurodegenerative and psychiatric disorders,
including LLD.
AGE-RELATED CHANGES IN GENE EXPRESSION APPEAR
TO BE, IN PART, GENETICALLY MODULATED
While molecular and chronological ages are highly correlated,
we have also reported individual deviations from predicted ages
(Erraji-Benchekroun et al., 2005; Glorioso et al., 2011). The fact
that molecular age can deviate from its chronological age suggests
that modulating factors exist and may contribute to one’s vulner-
ability to brain aging and to developing late-life brain disorders,
such as LLD. In the age-by-disease biological interaction hypoth-
esis we have proposed that those individuals with older predicted
molecular ages compared to their chronological age may not
only display greater biological brain aging, but may also be at
greater risk of age-gated brain diseases, because gene expres-
sion of disease-related genes would have proceeded further in
disease-promoting directions. Conversely, subjects with younger
age-dependent gene trajectories and lower predicted molecular
ages would be at lower risk, and may in fact display resiliency
against LLD and other late-life disorders (Figure 1B). Envi-
ronmental and genetic factors represent obvious candidates to
modulate the trajectory of biological aging.
In a proof-of-principle study, our laboratory sought to demon-
strate a genetic role in modulating the aging process. The
above-described “molecular age” assay was used to characterize
the brain tissue of individuals carrying different polymorphisms
of the sirtuin genes (Glorioso et al., 2011), a family of genes previ-
ously demonstrated to modulate age and longevity in nematodes,
insects, and rodents. We focused on SIRT5, due to prior report of
altered expression for that gene in a rodent model of anticipated
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brain aging (Sibille et al., 2007). This study found that subjects
carrying a low-expressing polymorphism of the SIRT5 gene had
molecular ages that were older than actual chronological age, as
measured in the three different areas of the cerebral cortex (i.e.,
BA9, BA24, and BA47) of human postmortem samples (Glorioso
et al., 2011). Interestingly, this effect was not demonstrated in
the amygdala, a brain area in which the low-expressing polymor-
phism of the SIRT5 gene does not appear to affect expression
levels of SIRT5 as it does in the cerebral cortex. These ﬁndings
at the molecular level are consistent with ﬁndings from studies of
brain structure with age that show robust decreases in gray matter
in the cerebral cortex but more variable decreases in the amyg-
dala (Good et al., 2001). The effect of the low-expressing SIRT5
polymorphism on molecular age was accompanied by expres-
sion changes for a set of genes whose products are localized to
the mitochondria, including PINK-1 and DJ-1, two Parkinson’s
disease-associated genes, in ways that would promote mitochon-
drial dysfunction-related diseases, including Parkinson’s disease.
This (correlative) proof-of-principle study suggests that factors
that affect brain aging can potentially place an individual at higher
risk for disease, through a mechanism by which it accelerates
brain biological aging, and thus promotes changes in expres-
sion of disorder-relevant genes in disease-causing directions.With
respect to Figure 1B, the low-expressing polymorphism of the
SIRT5 gene can be thought of a modulator that puts one on
the “at risk” trajectory. The converse of this model is that fac-
tors delaying age trajectories of gene changes may lead to younger
brain molecular aging and potential resiliency toward develop-
ing functional declines and age-related disorders, including LLD
(Figure 1B).
PUTATIVE MECHANISMS FOR AGE-RELATED CHANGES IN
GENE EXPRESSION
The mechanisms by which age-related changes in gene expression
occur are unknown. Candidate mediators include among others,
loss of telomere integrity, increased oxidative stress, and epigenetic
modiﬁcations.
LOSS OF TELOMERE INTEGRITY
Telomeres are regions of repetitive nucleotide sequences at each
end of a chromosome. One of the hypothesized functions of
telomeres is to deter the degradation of genes near the ends of
chromosomes by instead allowing repetitive telomeres to shorten,
a necessary part of chromosome replication. Telomeres are highly
susceptible to oxidative stress because of their high content of
guanines. As both chromosome replication and oxidative stress
increase with age, one would expect telomeres to shorten with
increased age. Indeed, in peripheral tissues, it has been consis-
tently demonstrated that telomeres become shorter as one ages
and once telomeres reach a critical length, irreversible arrest of
cell division or apoptosis is triggered (Hayﬂick and Moorhead,
1961; Chin et al., 1999; Sharpless and DePinho, 2004; Flores and
Blasco, 2009; Sahin andDePinho, 2012). Although telomere short-
ening has not yet been observed in the human brain, studies
suggest that peripheral telomere length is a biomarker for aging.
Leukocyte telomere shortening is positively correlated with the
chronicity of stress and depression (Epel et al., 2004; Wolkowitz
et al., 2011a) and is associated with incidence of age-related dis-
eases such as myocardial infarction, stroke, and shorter lifespan
(reviewed in Wolkowitz et al., 2011b). It is not known whether
telomere shortening increases the risk of LLD, however, given the
common pathway of aging and depression, the possibility cannot
be excluded.
Recent animal studies suggest that the putative link between
telomere integrity and depression-like behaviors extends to the
brain, and that this link may be mediated by telomerase activ-
ity (Zhou et al., 2011). In that study, the expression of telomerase
was decreased in the hippocampi of mice subjected to chronicmild
stress, andhippocampal infusionof a telomerase inhibitor induced
depressive-like behaviors that did not respond to antidepressant
treatment (Zhou et al., 2011). Given that neurogenesis has been
implicated in antidepressant responses in mice (Santarelli et al.,
2003) and that the proliferation capacity of neural stem cells highly
depend on telomerase activity (Ferron et al., 2009), the authors
suggested telomerase activity may play a role in linking mecha-
nisms of aging and depression (Zhou et al., 2011); although the
translation of these observations to humans is contentious, due to
very low rates of neurogenesis in adult human subjects (Bhardwaj
et al., 2006).
The anti-apoptotic role of telomerase is thought to reﬂect its
capacity of maintaining DNA integrity, however, recent stud-
ies have reported other putative functions (reviewed in Saretzki,
2009). Overexpression of telomerase reverse transcriptase (TERT),
protects mouse neurons from excitotoxicity by improving basal
mitochondrial membrane potential and Ca2+ uptake into mito-
chondria (Kang et al., 2004) and decreases cellular reactive oxygen
species (ROS; Ahmed et al., 2008). Furthermore, TERT mediates
the neurotrophic action of BDNF (Fu et al., 2002) and affects
the global pattern of gene expression in the direction of cell sur-
vival, including upregulation of growth promoting genes (FGF5,
EGFR, and etc.) and downregulation of cell-growth inhibitors
such as IGFBPs (Smith et al., 2003; Choi et al., 2008). Changes
in telomerase activity with age and MDD have yet to be explored
in the human brain. However, given the fact that neurotrophic
growth signaling, including reduced BDNF, is decreased in MDD
(Sen et al., 2008; Guilloux et al., 2011; Tripp et al., 2011), we can-
not exclude the possibility that telomeres and telomerase activity
may signiﬁcantly contribute to the mediation of stress and brain
aging.
INCREASED OXIDATIVE STRESS
Oxidative stress is the damage caused to cells as a result of an
imbalance between the production of ROS and the ability of the
cells to reduce the ROS or repair the resulting damage. The degree
of oxidative stress to cellular components, including DNA, corre-
lates positively with age (Joseph et al., 2005; Epel, 2009;Wolkowitz
et al., 2011b). Because of their highdemand for energy andpostmi-
totic status, neurons appear to be particularly sensitive to oxidative
stress and thus aging.
Oneway inwhich oxidative stressmay contribute to age-related
changes in gene expression is via its direct effect on DNA. Lu
et al. (2004) showed that age-related decrease in gene expres-
sion is related to the accumulation of oxidative DNA damage.
The underlying mechanism was suggested that promoter regions
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with high GC contents are speciﬁcally vulnerable to oxidative
damage. Oxidated promoter regions may potentially adopt dif-
ferent conformation and lose afﬁnity for transcription factors
(Lu et al., 2004). Damage on mitochondrial DNA (mtDNA),
which is considered extremely vulnerable to oxidation due
to its proximity to the site of ROS production, respiratory
chain, and the absence of protective histone (Lee and Wei,
2007), results in downregulation of genes related to respira-
tory chain and further, energy metabolism impairment (Lin
et al., 2002). Several studies showed that psychiatric diseases
including MDD, bipolar disorder, and schizophrenia are asso-
ciated with mitochondrial dysfunction (Rezin et al., 2009) and
that accumulation of mtDNA damage induces mood disorder-
like phenotypes as well as premature aging in mice (Trifunovic
et al., 2004; Kasahara et al., 2006). These results support the idea
that oxidative stress plays a role as a link between aging and
depression.
Another direct way in which oxidative stress may contribute
to age-related changes in gene expression is via its effect on tran-
scription factors. For example, ROS are able to activate nuclear
factor kappa B (NF-κB) by decreasing binding afﬁnity of the
inhibitory subunit, Iκ-B, to NF-κB, an observation made rele-
vant by the fact that NF-κB activity has been demonstrated to
increase with aging and depression (Toliver-Kinsky et al., 1997;
Koo et al., 2010). Also, transcription factors containing the zinc-
ﬁnger DNA binding motif appear to be especially susceptible to
damage from oxidative stress due to their high cysteine residue
content. As intracellular ROS accumulate, oxidation of the thiol
residues in cysteine occurs and binding afﬁnity for DNA is lost.
One of the zinc-ﬁnger transcription factors, Sp1, an ubiquitous
transcription factor for housekeeping genes and enzymes involved
in glucose metabolism and DNA synthesis, has been demon-
strated to have decreased DNA binding afﬁnity with advancing
age (Ammendola et al., 1992, 1994; Wu et al., 1996). Interestingly,
genes with lower afﬁnity binding sites to Sp1 are more inﬂu-
enced by oxidative stress than those containing high-afﬁnity sites
(Ammendola et al., 1992, 1994; Wu et al., 1996). Furthermore,
ROS decreases telomerase activity. Antioxidant treatment nor-
malizes catalytic activity of TERT and delays cellular senescence
(Haendeler et al., 2004).
In addition to the conformational changeof gene and transcrip-
tion factors, ROS can act on various cellular signaling pathways
to control gene expression. For example, ROS increase p53 sig-
naling, which has been implicated in various neurodegenerative
diseases and thought to mediate its effect by increasing expression
of genes related to cell cycle arrest, DNA repair, and apopto-
sis in response to cellular stressors such as DNA damage and
hypoxia (Lundberg et al., 2000). Another example is illustrated
by p38 MAP Kinase (MAPK). When p38 MAPK is activated by
oxidative stress, it promotes lamin B1 accumulation and expres-
sion of several transcription factors related to cellular senescence
and apoptosis such as p53, CREB, C/EBPβ, and ATF2 (Wagner
and Nebreda, 2009; Barascu et al., 2012). Interestingly, selec-
tive p38 MAPK deletion in serotonergic neurons produces stress
resilience in an animal model of depression by inhibiting sero-
tonin transporter translocation to plasma membrane (Bruchas
et al., 2011).
In summary, the main effect of oxidative stress on aging has
been thought to be the accumulation of toxic, inactive molecules
produced randomly by ROS. However, oxidative stress may also
have an active role in aging and related diseases, through direct
modiﬁcation of DNA and transcription factor integrity and
through indirect pathways regulating upstreammodulators. These
observations suggest that antioxidants may contribute to prevent-
ing biological changes and/or associated symptoms of depression,
in addition to their potential anti-aging effects.
EPIGENETIC MODIFICATIONS
Epigeneticmodiﬁcations, includingDNAmethylation andhistone
modiﬁcation, regulate gene expression without changing the pri-
mary DNA sequence. Though classically viewed as a permanent
event, recent data indicates that such modiﬁcations are inﬂuenced
by genetic and environmental factors in adult organisms, includ-
ing changes in methylation patterns across the lifespan (Numata
et al., 2012). At the genome level, DNA methylation decreases
with age. In contrast, CpG islands of many speciﬁc promoter
regions that are typically not methylated become methylated with
aging, including in promoters of tumor suppressor genes, estro-
gen receptor (ER), and insulin-like growth factor 2 (IGF2; Issa
et al., 1994, 1996; So et al., 2006; Numata et al., 2012). Changes in
DNA methylation at the glucocorticoid receptor, potentially due
to early-life stress, was also correlated with altered vulnerability to
psychiatric disorders and death by suicide in adults (McGowan
et al., 2009).
Similarly, histone modiﬁcations such as acetylation, phos-
phorylation, symoylation, and methylation change with age. It
was recently demonstrated that the aging-related deﬁcit of long-
term synaptic plasticity in the rodent hippocampus is related to
decreased BDNF expression secondary to decreased acetylation
of histones residing at the BDNF promoter region (Zeng et al.,
2011). This observation ﬁts well with human studies demonstrat-
ing reduced BDNF function in aging and depression (Webster
et al., 2002; Guilloux et al., 2011). Also, changes in histone mod-
iﬁcations in rodent systems may be protective against the effects
of stress (Covington et al., 2011; Uchida et al., 2011). In support
of a speciﬁc role for histone acetylation in age-related changes
in gene expression, sirtuins (NAD-dependent histone deacety-
lases) have been implicated in longevity in yeast and invertebrates
(Longo and Kennedy, 2006). A recent rodent study directly
links SIRT1 to the risk of anxiety-like behaviors through its
activity on monoamine oxidase A and serotonin levels (Libert
et al., 2011). In the same study, the authors reported associa-
tion between a single nucleotide polymorphism in the human
SIRT1 gene and the risk of various psychiatric disorders such
as anxiety disorder, panic disorder, and major depression. Fur-
thermore, overexpression of SIRT6 in mice has been reported
to increase lifespan and protect from diet-induced physiologi-
cal damage (Kanﬁ et al., 2010, 2012) and SIRT6 knockout mice
exhibit accelerated aging. Interestingly, decreased expression of
SIRT6 has been observed during MDD (Abe et al., 2011). How
SIRT6 mediates its effect on aging or is involved in MDD is
not clear, but its functions as an HDAC (Michishita et al., 2008;
Kawahara et al., 2009; Tennen et al., 2011) and in DNA repair
(Mao et al., 2011) suggest that it may contribute to protecting
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against aging and psychiatric illness by maintaining telomere
integrity or protecting against and repairing the effects of oxidative
stress.
Together, the occurrence of epigenetic modiﬁcations during
aging and in the context of neuropsychiatric disorders may thus
provide mechanistic underpinnings for the proposed age-by-
disease biological interaction hypothesis, through the dual role
of longevity and other age-associated genes.
SUMMARY AND IMPLICATIONS
We propose a novel framework for investigating the development
of late-life brain disorders, including LLD, which we term the age-
by-disease biological interaction hypothesis. This paper expands
uponan earlier versiondescribed elsewhere (McKinney andSibille,
2012). This hypothesis posits that symptoms of LLD and other
late-life brain disorders are the emerging properties of underly-
ing biological changes, which in turn are supported by normal
changes in the expression of multiple genes with age, including
disease-related genes changing in disease-causing directions. Here,
in addition to presenting the gene expression data on which the
hypothesis is based, we discussed molecular mechanisms that may
account for age-dependent gene expression changes, including
loss of telomere integrity, increased oxidative stress, and epige-
netic modiﬁcations. Importantly, this hypothesis complements
existing hypotheses, including the vascular, inﬂammatory, and
dementia prodromehypotheses of LLD,but it differs in that it posi-
tions age-dependent gene expression changes as the mechanism
potentially driving dysfunctions in multiple biological pathways,
including vascular, inﬂammatory, and neurotrophic functions.
A potential sequence of events is summarized in Figure 2. The
purpose of this paper was to discuss the general framework.
Examples of gene changes at the intersection of depression and
aging were provided (e.g., SST and BDNF), but the exact nature
and complexity of changes in multiple genes and pathways and
their relevance to disease pathways will be described in details
elsewhere.
The implications of this hypothesis for the prevention and
treatment of LLD and other late-life brain disorders are exciting.
Understanding the mechanisms mediating age-related changes in
gene expression is expected to provide insight into pathophysi-
ological mechanisms and potential targets for intervention into
these disorders. Identifying key upstream hub genes mediating
patterns of altered age-dependent changes would provide novel
targets for further investigations. Although sirtuins and BDNF
may represent obvious candidates, the large set of age-dependent
genes (∼10% of all genes; Erraji-Benchekroun et al., 2005) and
its overlap with genes previously implicated in brain disorders
(Glorioso et al., 2011) should be viewed as an enriched pool of
candidate genes. Targeting such upstream factors (transcription
or function) should represent productive research avenues. Early
candidate interventions may include known interventions such as
antidepressant medications, psychotherapy, exercise, and others.
Investigating how these known interventions affect age-dependent
changes in the function of critical genes may help in optimizing
their implementationwith respect to timing and duration of inter-
vention for age-dependent disorders. Further, identifying genetic
and environmental factors that slow or accelerate age-related
FIGURE 2 | Proposed sequence of biological events and putative
mediators for the age-by-disease biological interaction hypothesis.
From the top: Although its biological substrates are unknown, a
chronological clock drives age-related changes in gene expression. These
changes can be exacerbated by psychophysiological stress and/or genetic
variants, and placed on accelerated age trajectories. In this model,
age-related changes in telomeres, oxidative load and epigenetic landscape,
among other putative mechanisms, may represent a ﬁrst level of biological
events, which in turn affect basic cellular processes involved in regulating
gene expression (i.e., including DNA damage, altered structure and function
of transcription factors (TFs), and associated local cellular signaling). The
resulting changes in the global pattern of age-dependent gene expression
mediate the next set of deleterious biological events, exempliﬁed here by
increased inﬂammation, oxidative damage-related signaling, and changes in
neurotransmission. These two levels of changes are likely to reciprocally
interact. At the neural network and brain levels, the emerging properties of
those speciﬁc cellular events are expressed as senescence in normal aging
subjects and, in subjects at risk, as age-related symptom dimensions
and diseases, including depression. Notably, the degree of individual
vulnerability is thought to be under genetic and environmental control,
so decreased vulnerability may mediate resiliency through the same
pathways.
changes in gene function may lead to individualized strategies
aimed at promoting resilience and successful aging. Other entry
points and targets for intervention are likely to arise out of under-
standing the mechanisms by which gene expression changes with
age, including determining the role of telomere integrity, oxidative
stress, and epigenetic modiﬁcations. Finally, for the broader ﬁelds
of aging and gerontology, the implication of this hypothesis is that
it brings together research on normal aging more closely with the
investigation of neuropsychiatric and neurodegenerative diseases.
Indeed, our data ﬁrmly support the assertion that they may in fact
be related facets of similar biological processes, and also provide
the basis for a putative mechanism of age-by-disease biological
interactions.
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